Implantica AG (IMP-A-SDB.ST)
SEK 37.65
(2.45%)
SEK 37.65
(2.45%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 584 Thousand EUR | 9.91% |
| 2022 | 817 Thousand EUR | 0.0% |
| 2021 | - EUR | -100.0% |
| 2020 | 86 Thousand EUR | -96.1% |
| 2019 | 2.2 Million EUR | 1026.95% |
| 2018 | 195.83 Thousand EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 486 Thousand EUR | -16.78% |
| 2024 Q2 | - EUR | 48.35% |
| 2023 Q1 | 740 Thousand EUR | -9.42% |
| 2023 Q3 | 628 Thousand EUR | -8.59% |
| 2023 FY | 584 Thousand EUR | -28.52% |
| 2023 Q4 | 584 Thousand EUR | -7.01% |
| 2023 Q2 | 687 Thousand EUR | -7.16% |
| 2022 Q1 | - EUR | 0.0% |
| 2022 Q2 | - EUR | 0.0% |
| 2022 Q3 | - EUR | 0.0% |
| 2022 Q4 | 817 Thousand EUR | 0.0% |
| 2022 FY | 817 Thousand EUR | 0.0% |
| 2021 Q3 | 4000.00 EUR | -87.1% |
| 2021 Q1 | 57 Thousand EUR | -33.72% |
| 2021 Q2 | 31 Thousand EUR | -45.61% |
| 2021 FY | - EUR | -100.0% |
| 2021 Q4 | - EUR | -100.0% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q3 | - EUR | -100.0% |
| 2020 Q2 | 7.61 Million EUR | 0.0% |
| 2020 FY | 86 Thousand EUR | -96.1% |
| 2020 Q4 | 86 Thousand EUR | 0.0% |
| 2019 FY | 2.2 Million EUR | 1026.95% |
| 2019 Q4 | 2.2 Million EUR | 0.0% |
| 2018 FY | 195.83 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.964% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 99.964% |
| Arcoma AB | 3.87 Million SEK | 84.921% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 99.749% |
| BICO Group AB (publ) | 1.85 Billion SEK | 99.968% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 99.648% |
| CellaVision AB (publ) | 64.7 Million SEK | 99.097% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | -28.634% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.8 Million SEK | 67.556% |
| Duearity AB (publ) | 10.58 Million SEK | 94.481% |
| Dignitana AB (publ) | 19.1 Million SEK | 96.943% |
| Episurf Medical AB (publ) | 5.2 Million SEK | 88.769% |
| Getinge AB (publ) | 8.07 Billion SEK | 99.993% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 92.921% |
| Iconovo AB (publ) | 7.72 Million SEK | 92.44% |
| Integrum AB (publ) | 6.42 Million SEK | 90.909% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -183.462% |
| Mentice AB (publ) | 9.55 Million SEK | 93.889% |
| OssDsign AB (publ) | 3.15 Million SEK | 81.46% |
| Paxman AB (publ) | 13.57 Million SEK | 95.696% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 97.183% |
| SciBase Holding AB (publ) | 6.79 Million SEK | 91.408% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 31.78 Million SEK | 98.163% |
| Sedana Medical AB (publ) | 4.3 Million SEK | 86.438% |
| Senzime AB (publ) | 11.46 Million SEK | 94.908% |
| SpectraCure AB (publ) | 6.71 Million SEK | 91.306% |
| Stille AB | 62.94 Million SEK | 99.072% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 99.972% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 98.142% |